Takeda Pharmaceutical
Michal Ayalon, PhD, is an experienced leader in the biopharmaceutical industry with a robust background in research and development. Currently serving as the Head of In Vitro Pharmacology for Global Biologics at Takeda since December 2023, Michal has previously held positions such as VP Translational Science at xilis and Vice President of Research and Development at Kamada, where responsibilities included R&D strategy and non-clinical activities. Additional experience includes leading R&D at 89bio, overseeing product development at Teva Pharmaceuticals, and managing various roles at Galmed Pharmaceuticals and Immune Pharmaceuticals. Michal holds a PhD in Cell Biology and Immunology and an MSc in Cell/Cellular and Molecular Biology from Tel Aviv University.
This person is not in any teams
This person is not in any offices
Takeda Pharmaceutical
177 followers
For more than 230 years, Takeda has brought hope to people around the world through its people-centered and innovation-driven approach to science and medicine. As a global pharmaceutical leader, Takeda focuses on solving unmet needs where it can make a real difference—and on putting patients first. Its therapeutics focus is oncology, gastroenterology, and the central nervous system, as well as vaccines.